Daily News Podcast

Intranasal esketamine gets FDA support for refractory depression

Publish date: February 15, 2019

 

FDA panels are backing intranasal esketamine for refractory depression. Also today, the office of the National Coordinator of Health Information Technology aims to help doctors and patients with information sharing, most physicians think that health care costs and access are unlikely to improve in 2019, and vaccination and antiviral treatment do not affect the risk of stroke following shingles.
Amazon Alexa
Apple Podcasts
Google Podcasts
Spotify

Recommended Reading

E-cigarettes beat nicotine patch for smoking cessation
MDedge Internal Medicine
ONC aims to help docs, patients with information sharing in proposed rule
MDedge Internal Medicine
Opioids often prescribed in low-income areas
MDedge Internal Medicine
Love hormone plein air, posh preused Kleenex, and dieting plague vectors
MDedge Internal Medicine
Adolescents’ screen time tied to more depression, less sleep
MDedge Internal Medicine
Take action to mitigate CVD risk in RA patients
MDedge Internal Medicine
Does adherence to a Mediterranean diet reduce the risk of Parkinson’s disease?
MDedge Internal Medicine
What comes first with SGLT2 inhibitors – diabetes or heart failure?
MDedge Internal Medicine
How are you at coping with transparency?
MDedge Internal Medicine
TNFi use may not affect joint replacement rates for RA patients
MDedge Internal Medicine